Canon unveils Aplio me X ultrasound system at Euroson 2026

AuntMinnieEurope.com staff writers
Jun 18, 2026

Canon Medical Systems unveiled the Aplio me X diagnostic ultrasound system at Euroson 2026, the Congress of the European Federation of Societies for Ultrasound in Medicine and Biology, in Lublin, Poland.

Aplio me X ultrasound systemAplio me X ultrasound systemCanon

The Aplio me X features AI-assisted workflows powered by Canon's Altivity AI platform and is designed for high-end routine ultrasound in daily clinical practice. The system includes up to four hours of battery-powered operation to support use across a range of clinical environments. It is built on Canon's scalable architecture with high-performance processing, the firm said.

Latest in Ultrasound
Liver
E-Scopics wins FDA clearance for hepatoscope technology
June 17, 2026
Dr. Alba Pugliesi
Video: Dr. Alba Pugliesi on what keeps her dreams big
June 16, 2026
Ukio Ultrasound Manifesto Launch
U.K. ultrasound consortium releases manifesto
June 16, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Image-guided focal laser ablation effective for prostate cancer
June 3, 2026
Related Stories
Europe Data Resized
Imaging Informatics
Making data speak the same language: Harmonization and health data
Canon's new Aplio beyond ultrasound scanner. Image courtesy of Canon.
ECR 2025
Canon highlights ultrasound and CT lung screening at ECR 2025
Canon Rsna 2019
CT
Canon releases new CT system in the U.K.
Liver
Industry News
E-Scopics wins FDA clearance for hepatoscope technology
More in Ultrasound
E-Scopics wins FDA clearance for hepatoscope technology
By AuntMinnie.com staff writers
The technology demonstrated a 0.93 correlation coefficient with MRI-based proton density fat fraction.
June 17, 2026
Liver
Video: Dr. Alba Pugliesi on what keeps her dreams big
By Claudia Tschabuschnig
In a video interview, radiologist Dr. Rosa Alba Pugliesi shares how limits are only in your head.
June 16, 2026
Dr. Alba Pugliesi
U.K. ultrasound consortium releases manifesto
By AuntMinnieEurope.com staff writers
Document outlines actions to strengthen diagnostic ultrasound services.
June 16, 2026
Ukio Ultrasound Manifesto Launch
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Wearable ultrasound patch shows promise for continuous fetal monitoring
By AuntMinnie.com staff writers
The patch uses tracking algorithms to follow the umbilical cord as it moves.
May 28, 2026
A wearable ultrasound patch could provide continuous monitoring of the fetus and umbilical cord during pregnancy.
EDAP, Telix to explore collaboration
By AuntMinnie.com staff writers
The companies will focus on combining EDAP’s Focal One Robotic HIFU treatment and Telix’s PSMA PET imaging agents.
May 14, 2026
Prostate Imaging
Echosens names Romain Baujard as group CEO
By AuntMinnie.com staff writers
Echosens has appointed Romain Baujard as group chief executive officer, succeeding Dominique Legros.
April 28, 2026
Echosens Romain Baujard Thumb
VR glasses soothe patients undergoing TRUS-guided prostate biopsy
By Amerigo Allegretto
Prostate biopsy patients who view nature-based video content via VR glasses reported having less anxiety and more comfort.
April 8, 2026
Virtual Reality Goggles2 400
Diagnoly launches Fetoly fetal ultrasound AI app on iOS
By AuntMinnie.com staff writers
Following a collaboration with GE HealthCare, Diagnoly has launched its Fetoly fetal ultrasound AI application on iOS.
April 2, 2026
Diagnoly Fetoly Ai Ultrasound I Os
Training, standards needed for radiographers to perform POCUS
By Amerigo Allegretto
Training, standardization, and careful management are needed for radiographers to regularly use point-of-care ultrasound (POCUS) in imaging departments.
March 19, 2026
Thérèse Herlihy, PhD, at ECR 2026 discusses the state of radiographer-performed POCUS and what's needed for expanded scope of practice.
Esaote unveils new IR ultrasound systems, MRI AI at ECR 2026
By AuntMinnieEurope.com staff writers
Esaote has launched two new ultrasound systems for interventional radiologists (IR).
March 6, 2026
Esaote's MyLab385 GTS
Harrison.ai expands Open Platform with 4 new AI partners
By AuntMinnieEurope.com staff writers
Harrison.ai will add the AI tools of AIRAmed, Koios Medical, Lunit, and Nanox AI to its Open Platform ecosystem.
March 4, 2026
Business Partner Handshake Intelligence
Page 1 of 125
Next Page